Over the past decades, human papillomavirus (HPV) vaccines have been approved in numerous countries, producing two very positive trends.
According to Merck's financial results for 2024, its market-leading HPV vaccines, GARDASIL and GARDASIL 9, produced $8.6 billion in sales, with higher demand in most international regions, particularly Japan.
-
-
COVID-19 Pandemic Challenges Osteoporosis Management
-
AstraZeneca, J&J Resume U.S. COVID-19 Vaccine Trials
-
Survival From COVID-19 High in Patients With Psoriasis
-
FDA Needs More Safety Data on COVID-19 Vaccines, Experts Say
